Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
600196
Rang in Aktien
#2197
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical... Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumors and hematologic malignancies, as well as immune-inflammatory disorders, metabolism and digestive systems, anti-infection, central nervous system, cardiovascular system, and APIs and intermediates. It also offers mRNA vaccines; medical aesthetic devices, such as medical aesthetic capital equipment, aesthetic dentistry, injectables, and personal care business units; mechanical ventilation devices under the Breas brand; and mobile pre-hospital care; professional in-hospital surgery and covers medical devices; and high-end surgical robots and medical consumables. In addition, the company provides diagnostics solutions comprising biochemical diagnostics, immune diagnostics, molecular diagnostics, microbiological diagnostics, pathological diagnostics, and chronic care management; and healthcare services, specialized medical treatment, online and offline medical services, and insurance services. Further, it engages in the operation of hospitals; and distribution and retail of healthcare products. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
Aktienkurs
$3.40
Marktkapitalisierung
$9.07B
Veränderung (1 Tag)
-1.61%
Veränderung (1 Jahr)
-16.08%
Land
CN
Handel Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196)
Kategorie
Healthcare
Gewinn für Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196)
Gewinn im 2026 TTM: 0
Laut den aktuellen Finanzberichten von Shanghai Fosun Pharmaceutical (Group) Co., Ltd. betragen die aktuellen Gewinne des Unternehmens 0. Im Jahr 2026 erzielte das Unternehmen einen Gewinn von 0, gleich wie dem Gewinn im Jahr 2026, der 0 betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Shanghai Fosun Pharmaceutical (Group) Co., Ltd. von 2001 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2025 | $730.66M | 27.92% |
| 2024 | $571.20M | 23.86% |
| 2023 | $461.19M | -30.46% |
| 2022 | $663.16M | -30.25% |
| 2021 | $950.72M | 32.77% |
| 2020 | $716.07M | 10.17% |
| 2019 | $649.94M | 24.89% |
| 2018 | $520.40M | -16.64% |
| 2017 | $624.28M | 21.36% |
| 2016 | $514.42M | -0.93% |
| 2015 | $519.24M | 18.33% |
| 2014 | $438.82M | 15.05% |
| 2013 | $381.42M | 12.03% |
| 2012 | $340.46M | 24.30% |
| 2011 | $273.89M | 50.41% |
| 2010 | $182.10M | -61.92% |
| 2009 | $478.18M | 290.45% |
| 2008 | $122.47M | 18.23% |
| 2007 | $103.59M | 135.84% |
| 2006 | $43.92M | 31.65% |
| 2005 | $33.36M | 92.26% |
| 2004 | $17.35M | -58.15% |
| 2003 | $41.46M | 96.02% |
| 2002 | $21.15M | 8.96% |
| 2001 | $19.41M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | - |
IN
|
